We learned from Yifan Pharmaceutical that the company made new progress this year. Among them, the cumulative number of F-627 shipments exceeded 500,000 units, an increase of more than 80% over the previous year. It is expected to trigger accounting confirmation conditions for domestic sales milestones, of which more than 46,000 were shipped to the US market; in addition, the cumulative number of shipments of the innovative drug Inicon in 2025 more than tripled year on year. At the same time, the company has built a translational medicine team focusing on solid tumors. The sales volume of its main product, Heroda, is expected to achieve year-on-year double-digit growth. In the future, the company will further enrich the solid tumor product pipeline and lay out more collaborative products.

We learned from Yifan Pharmaceutical that the company made new progress this year. Among them, the cumulative number of F-627 shipments exceeded 500,000 units, an increase of more than 80% over the previous year. It is expected to trigger accounting confirmation conditions for domestic sales milestones, of which more than 46,000 were shipped to the US market; in addition, the cumulative number of shipments of the innovative drug Inicon in 2025 more than tripled year on year. At the same time, the company has built a translational medicine team focusing on solid tumors. The sales volume of its main product, Heroda, is expected to achieve year-on-year double-digit growth. In the future, the company will further enrich the solid tumor product pipeline and lay out more collaborative products.